Novel Antiviral Agents: Synthesis, Molecular Modelling Studies and Biological Investigation

© 2022 by the authors; CC BY-NC-ND license

dialysis; end-stage kidney disease; hepatitis C virus; sofosbuvir; sustained viral response; carbapenem-resistant; Pseudomonas aeruginosa; bacteriophage; hydrogel; thermal injury model; histopathology; foot-and-mouth disease virus (FMDV); RNA-dependent RNA polymerase (RdRp); 3D polymerase (3D^pol); small molecule; virtual screening; antiviral cell-based assay; antiviral agent; PSP; HIV; proteomics; cofilin-1; PKR; IRE1α; UPR; Zika virus; peptide; antiviral; DV2 peptide; dengue virus; flavivirus; deep learning; SARS-CoV-2 M^pro; transfer learning; drug development; natural compound; virus; picornavirus; enterovirus; antiviral; edible plant; PI4KB; influenza; neuraminidase inhibitors; noncompetitive inhibition; virtual screening; ligand docking; screening pitfalls; screening problems; HIV-1 gp120 V3 loop; chemokine receptor CXCR4; molecular recognition; D-peptide; HIV-1 entry; antiviral agents; coronaviruses; viral entry; antimicrobial; coronavirus; abietane; dehydroabietylamine; phenol; phthalimide; COVID-19; microscale thermophoresis; SLC6A20 amino acid transporter; antiviral agents; Dengue virus; natural compounds; NS5 protein; antiviral activity; antiviral agents; heterocycles; natural products; Structure Activity Relationship (SAR); synthetic methods; SARS-CoV-2; NSP3; macrodomain-I; medicinal compounds; computational biology; n/a